氯吡格雷反应性的研究进展  

Research Progress of Clopidogrel Responsiveness

作　　者：马文芳[1] 梁岩[1] 

机构地区：[1]中国医学科学院北京协和医学院北京阜外心血管病医院,北京100037

出　　处：《心血管病学进展》2014年第5期531-535,共5页Advances in Cardiovascular Diseases

摘　　要：对于急性冠状动脉综合征和经皮冠状动脉介入治疗患者,氯吡格雷联合阿司匹林的双联抗血小板治疗已成为药物治疗的核心手段。然而,越来越多的证据显示不同生物个体之间存在抗血小板治疗反应的多样性;特别是氯吡格雷低反应性,与临床上反复缺血、脑卒中、支架内血栓形成等不良事件相关;机制尚未完全阐明,涉及遗传、代谢、基因多态性、药物相互作用等方面。现就氯吡格雷反应性的研究进展做一综述。Dual antiplatelet therapy with aspirin and clopidogrel is at the core of the medical treatment of patients with acute coronary syndrome and those undergoing pereutaneous coronary intervention. However, increasing evidence shows the existence of variability of platelet response between individuals during antiplatelet therapy. In patients, a lack of response to elopidogrel is associated with recurrent isehe- mia, stroke, stem thrombosis and other adverse clinical events. The mechanisms for a lack of response have not been fully clarified, hut may involve genetics, metabolism, gene polymorphisms, drug interactions, and more. This article reviews current research progress involving elopidogrel responsiveness.

关 键 词：冠心病 急性冠状动脉综合征 氯吡格雷反应性 血小板功能检测 

分 类 号：R541.4[医药卫生—心血管疾病]